BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate

Dow Jones

04/03

By Colin Kellaher

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study.

BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival.

BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker.

However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2025 06:34 ET (10:34 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524723402"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524723402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524723402?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 18:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524723402","market":"other","top_or_hot":-1,"title":"BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. \n</p>\n<p>\n  BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival. \n</p>\n<p>\n  BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker. \n</p>\n<p>\n  However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 06:34 ET (10:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-03 18:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. \n</p>\n<p>\n  BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival. \n</p>\n<p>\n  BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker. \n</p>\n<p>\n  However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 06:34 ET (10:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524723402","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524723402","pubTimestamp":1743676440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study.BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival.BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker.However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1588":"回港中概股","BK1161":"生物科技","BK1500":"做空集合股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","ONC":"百济神州","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4139":"生物科技","06160":"百济神州"},"translate_title":"百济神州放弃Ociperlimab肺癌候选药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1,"ONC":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. \n\n\n  BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival. \n\n\n  BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker. \n\n\n  However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 06:34 ET (10:34 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}